Toripalimab, Induction Chemotherapy, Radiation Therapy With Omega-3 for Locally Advanced Nasopharyngeal Carcinoma

Sex: All

Ages: 18 Years – 65 Years

Healthy volunteers: No

Phase: PHASE2

Enrollment: 30

Sponsor: Affiliated Hospital of Guangdong Medical University

Location: Affiliated Hospital of Guangdong Medical University Zhanjiang Guangdong

Summary

The aim of this study is to evaluate the efficacy, adverse reactions, nutritional status analysis, and quality of life analysis of Toripalimab Plus Induction Chemotherapy Followed by Radiation Therapy Combined with Omega-3 in the treatment of locally advanced nasopharyngeal carcinoma.

Eligibility Criteria

Inclusion Criteria: * Written informed consent can be provided, and understanding and compliance with research requirements and evaluation schedules are required. * On the date of signing the informed consent form, the age range is between 18 and 65 years old (or the legal age specified by local laws). * Pathological diagnosis is non keratinizing carcinoma of the nasopharynx (differentiated or undifferentiated, i.e. WHO classification II or III). * Clinical staging is anyTN2-3M0 or T4N1M0 (AJCC8th/UICC staging). * ECOG score is 0-1 points. * Hemoglobin (HGB) ≥ 90g/L, white blood cell (WBC) ≥ 4.0 × 109/L, platelet (PLT) ≥ 100 × 109/L. * Liver function: ALT and AST\

Interested in this study? View the official listing for contact and enrollment details.

View on ClinicalTrials.gov

Source: ClinicalTrials.gov (NCT07136519). StuddyBuddy aggregates publicly available trial information.